SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

FMC Corp. is an agricultural sciences company, which engages in the provision of solutions to growers and development of pipeline in crop protection, plant health, agriculture, pest control, and turf management. It offers insect control products under the Rynaxypyr and Cyazypyr brands. The company was founded by John Bean in 1883 and is headquartered in Philadelphia, PA.

FMC Corp.

FMCs sharply reduced third-quarter outlook, driven by weak demand, excess distributor inventory and a major pricing reset, has intensified concerns about its business and heavy debt. Traders are divided between viewing the reset and debt-reduction measures as a path to recovery and fearing further deterioration or bankruptcy.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Johnson & Johnson

Speculation that Johnson & Johnson could acquire Sellas Life Sciences is a recurring topic, with traders pointing to alleged executive connections and J&Js oncology ambitions; no deal has been confirmed. Traders are also debating J&Js earnings reaction: stronger-than-expected results and raised guidance were offset by weak MedTech growth and litigation concerns, while some view the pullback as a buying opportunity.

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services. The company was founded in June 2002 by George Byron Brooks, Michael Gorton, and Gary Wald and is headquartered in New York, NY.

Teladoc Health Inc

Discussion centers on whether Teladoc can show a credible turnaround in its quarterly results, especially stabilizing BetterHelp as it shifts from cash-pay to insurance amid concerns about declining revenue, profitability and management execution. Bulls cite potential insurance growth, Teladoc One and short-interest dynamics, while skeptics remain doubtful; squeeze claims are speculative.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Discussion centers on Lillys obesity and diabetes franchise and expectations for quarterly results, with traders pointing to Mounjaro and Zepbound demand, Foundayo uptake, and pipeline prospects. Bulls cite growth and healthcare-sector strength, while skeptics flag Lillys high valuation and competition from Novo Nordisk and emerging obesity-drug rivals.

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

AMGEN Inc.

Amgens attention is centered on Phase 3 results showing IMDELLTRA with AstraZenecas IMFINZI reduced the risk of death in first-line extensive-stage small-cell lung cancer. Traders are treating the survival findings as a positive oncology catalyst, while some also point to favorable Phase 3 TEZSPIRE results in eosinophilic esophagitis.

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. The company was founded in 1913 and is headquartered in Cambridge, the United Kingdom.

Astrazeneca plc

AstraZeneca PLC

Speculation about a potential AstraZenecaBristol Myers Squibb merger has drawn attention, with traders debating the deals strategic value and financial risks. Reports that no discussions took place cooled the rumor, though some community members remain skeptical.

Visa, Inc. engages in the provision of digital payment services. It also facilitates global commerce through the transfer of value and information among a global network of consumers, merchants, financial institutions, businesses, strategic partners, and government entities. It offers debit cards, credit cards, prepaid products, commercial payment solutions, and global automated teller machines. The company was founded by Dee Hock in 1958 and is headquartered in San Francisco, CA.

Visa Inc - Ordinary Shares - Class A

Visa Inc

Visa is drawing attention ahead of its fiscal-year earnings report, with traders focused on margin and forward guidance rather than a likely headline beat. Sentiment is split between bullish momentum near record highs and concerns that expectations are stretched, with some traders watching for a post-report pullback.

VanEck ETF Trust - VanEck Semiconductor ETF

VanEck Semiconductor ETF

A sharp pullback in semiconductor stocks has put SMH at the center of a debate over whether worries about AI spending, financing and chip-sector valuations signal a deeper downturn. Traders are split between expecting more downside and looking for an oversold bounce, with some arguing that strong AI demand and continued capital spending support the longer-term outlook.

Occidental Petroleum Corp. engages in the exploration and production of oil and natural gas. It operates through the following segments: Oil and Gas, Chemical, and Midstream and Marketing. The Oil and Gas segment explores for, develops and produces oil and condensate, natural gas liquids, and natural gas. The Chemical segment manufactures and markets basic chemicals and vinyls. The Midstream and Marketing segment purchases, markets, gathers, processes, transports and stores oil, condensate, natural gas liquids, natural gas, carbon dioxide, and power. The company was founded in 1920 and is headquartered in Houston, TX.

Occidental Petroleum Corp.

The ongoing shale-oil antitrust case is drawing attention after the judge deferred jurisdictional rulings for Hess and Pioneer pending limited discovery, with an October status conference ahead; traders emphasize that the claims remain unresolved. Bullish chatter also points to oil-linked strength and a possible technical breakout, though some traders are watching resistance.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomms planned performance-focused global layoffs are drawing attention, with traders divided over whether the restructuring signals tighter cost discipline or reflects underperformance. The discussion also centers on the stock holding up relatively well against semiconductor peers and whether the upcoming earnings report will validate a rebound, while skeptics remain wary of its recent weakness.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Citi’s Montagu: Strong bid for growth lifts Nasdaq positioning to 3-year high

Investing.com -- Investor appetite for growth surged last week, pushing bullish positioning in the Nasdaq to its highest level in three years, according to  Citigroup  (NYSE:C).

U.S. and Asia equity positioning surges as geopolitical tensions ease

Investing.com -- Bullish investor positioning in U.S. equities rose sharply last week as geopolitical tensions between Iran and Israel de-escalated, lifting sentiment across risk assets, according to Citi’s new weekly report.

Citi sees bullish turn in U.S. stocks, mixed signals across global markets

Investing.com --  Citigroup  (NYSE:C) sees a bullish turn in U.S. equities, led by increased investor positioning in major indexes, while global markets reflect more mixed signals.

Citi says bearish flows return as investors react to trade, fiscal policy risks

Investing.com -- Investor positioning in U.S. equities has moderated, with a rise in bearish flows driven by uncertainty around trade policy and mounting fiscal concerns, according to  Citigroup  (NYSE:C).

Investor positioning stabilizes amid easing tariff threats, strong earnings: Citi

Investing.com -- Recent moderation in tariff threats, coupled with strong corporate earnings, has driven a rebound in U.S. equity positioning, bringing exposure across major indexes close to neutral, according to  Citigroup  (NYSE:C) strategists led by Chris Montagu.

Citi's Montagu says further downside risks remain persistent for the S&P 500

Investing.com -- Citi’s Chris Montagu is warning that downside risks for U.S. equities, particularly the S&P 500, remain a concern as bearish positioning picks up again following a brief period of relief after the latest pause in tariff announcements.

Citi's Montagu warns losses in S&P 500 could amplify future moves

Investing.com -- U.S. equity flows were led by short covering over the past week, particularly in the S&P 500 and Nasdaq, though there was limited evidence of fresh long positioning, according to Citi strategists.

Nasdaq positioning returns to neutral ahead of tariffs announcements: Citi

Investing.com -- Short flows into U.S. equities have brought net positioning in the Nasdaq back to neutral, matching the S&P 500 levels as markets brace for upcoming tariff announcements, according to Citi strategists.

Citi’s Montagu: U.S. equities positioning remains neutral, de-grossing in Nasdaq

Investing.com -- The S&P 500 and Nasdaq saw mixed positioning flows over the past week, offsetting any large movements in overall positioning and keeping levels near neutral, Citi strategists said in a report.

S&P 500 positioning back to neutral, but increasingly bearish for small caps: Citi

Investing.com -- Positioning in the S&P 500 has returned to neutral last week after sharply pulling back from the elevated bullish levels of late January, Citi strategists revealed, citing ongoing uncertainty over U.S. trade policy.

ETF Series Solutions Trust - Loncar China BioPharma ETF

Neutral Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Feed

News

Sentiment

Fundamentals

Info

CHNA ETF Series Solutions Trust - Loncar China BioPharma ETF

Latest CHNA News